Targets › NMDA
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Jul 2027.
Open in Phaseline: the race on NMDA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital Universitario La Fe | Opioid-Free Anesthesia (OFA) Multimodal non-opioid protocol: alpha-2 agonist (Dexmedetomidine), sodium channel blocker | ADRA2A, Ion channels, NMDA | Phase 1 | Pain Management | Jul 2027 |
Pain Management (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.